Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.
Azacitidine Combo Shows High Response Rates in FLT3-Mutated AML
February 26th 2024A phase 1/2 study found that using azacitidine, venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia yielded high rates of complete response and complete response with incomplete hematologic recovery.